Eyam Health

Eyam Health is a Vancouver-based biotechnology company developing next-generation biologics through its proprietary AI and self-amplifying nucleic acid platforms. At the heart of Eyam’s innovation are two synergistic technologies: Gemini, a modular, lipid-free delivery system that supports large, multi-gene payloads with cold-chain independence; and Jennerator, an AI-powered platform that rapidly identifies and optimizes immunologically relevant targets for biologic design.

By combining advances in synthetic biology, immunology, and machine learning, Eyam enables faster, more precise development of biologics—spanning vaccines, antibody therapeutics, and gene and cell-based treatments. Its delivery platform eliminates the need for traditional lipid nanoparticles and reduces reliance on ultra-cold storage, significantly lowering cost and expanding global accessibility.

Eyam’s pipeline addresses urgent and high-impact areas including infectious disease, cancer, chronic and rare diseases, with funded projects already in place with global pharmaceutical companies, ventures, and global health drivers like the Gates Foundation. The company operates with a lean, mission-driven model focused on high-impact science and translational success, supported by a robust IP portfolio.

With a vision to democratize access to biologics and reshape how biologic drugs are designed, manufactured, and delivered, Eyam Health is advancing a new frontier in precision, scalable, and globally accessible healthcare solutions.